Talazoparib + enzalutamide beneficial in metastatic prostate cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according to a study presented at the American ...
Feb 17, 2023
0
3